{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049866","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.405818+00:00","generated_at":"2026-05-16T23:35:27.240261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Esperion Q3 total revenue up 69% to $87.3M; net loss $0.16/share","bullets":["U.S. net product revenue $40.7M (+31% YoY); total collaboration revenue $46.7M (+128% YoY).","Net loss $31.3M ($0.16 diluted EPS) vs $29.5M loss ($0.15) in Q3 2024.","Settled with Dr. Reddy's and three other ANDA filers; generic entry blocked until April 2040.","Partner Otsuka received Japan approval and preliminary pricing for NEXLETOL, triggering milestone payments.","Company reiterates 2025 opex guidance of $215-235M; expects sustainable profitability from Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049866","json":"https://secwatch.observer/filing/0001628280-25-049866.json","markdown":"https://secwatch.observer/filing/0001628280-25-049866.md","text":"https://secwatch.observer/filing/0001628280-25-049866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025049866/0001628280-25-049866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025049866/espr-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:35:27.240261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}